A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF SUBJECTS WITH ACTIVE BEHCET'S DISEASE

Trial Profile

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF SUBJECTS WITH ACTIVE BEHCET'S DISEASE

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Behcet's syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 26 Oct 2017 According to a Celgene Corporation media release, full data-set will be presented at a future medical meeting. These data form the basis of global regulatory applications that are planned beginning in 2018.
    • 26 Oct 2017 Primary endpoint (Oral Ulcers) has been met, according to a Celgene Corporation media release.
    • 27 Jul 2017 According to a Celgene Corporation media release, data from this trial are expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top